Display options
Cite
Foster RH, Goa KL. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder. CNS Drugs. 1997;8(2):163-88doi: 10.2165/00023210-199708020-00010.
Foster, R. H., & Goa, K. L. (1997). Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder. CNS drugs, 8(2), 163-88. https://doi.org/10.2165/00023210-199708020-00010
Foster, R H, and Goa, K L. "Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder." CNS drugs vol. 8,2 (1997): 163-88. doi: https://doi.org/10.2165/00023210-199708020-00010
Foster RH, Goa KL. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder. CNS Drugs. 1997 Aug;8(2):163-88. doi: 10.2165/00023210-199708020-00010. PMID: 23338224.
Copy Download .nbib Format: NLM
Share it on

CNS Drugs. 1997 Aug;8(2):163-88. doi: 10.2165/00023210-199708020-00010.

Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.

CNS drugs

R H Foster, K L Goa

Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand, [email protected].

PMID: 23338224 DOI: 10.2165/00023210-199708020-00010

Abstract

SYNOPSIS: Paroxetine is the first selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitor (SSRI) to be approved for the treatment of patients with panic disorder with or without agoraphobia. It is a highly selective inhibitor of presynaptic serotonin reuptake and does not interact with adrenergic, dopaminergic, histaminergic or serotonergic receptors to any significant extent. Oral paroxetine 10 to 60 mg/day is significantly more effective than placebo in reducing the frequency of panic attacks and improving associated symptoms, as shown in short term trials in patients with panic disorder with or without agoraphobia. The efficacy of the drug was maintained during up to 6 months'; treatment, and continued therapy reduced the risk of relapse. Oral paroxetine 10 to 60 mg/day was at least as effective as clomipramine 10 to 150 mg/day, but appeared to have a more rapid onset of effect, in a placebo-controlled trial. The tolerability profile of paroxetine is similar to that established for other SSRIs and is characterised by adverse events such as nausea, headache, somnolence, dry mouth, tremor, insomnia, asthenia, sweating, constipation, dizziness and sexual dysfunction. Paroxetine was better tolerated overall than clomipramine and was associated with a lower incidence of certain anticholinergic events (such as dry mouth and constipation) in a comparative trial. It is not associated with the type of dependence seen with benzodiazepines, and it appears to be safer in overdose than the tricyclic antidepressants. Paroxetine 20 or 30mg does not significantly impair psychomotor function or interact with alcohol (ethanol). In conclusion, the good tolerability profile of paroxetine, including lack of dependence potential and relative safety in overdose, makes it attractive for the treatment of patients with panic disorder. It appears to be at least as effective as clomipramine in reducing panic attacks and associated symptoms. Although further trials to compare the efficacy and tolerability of paroxetine with that of other tricyclic agents (especially Imipramine), high-potency benzodiazepines and monoamine oxidase inhibitors are needed, the drug appears to have the potential to become a first-line treatment for panic disorder.

PHARMACODYNAMIC PROPERTIES: Paroxetine increases serotonergic neurotransmission by inhibiting presynaptic reuptake of serotonin (5-hydroxytryptamine; 5-HT) and thereby increasing the level of the neurotransmitter at the synaptic cleft. In vitro, it is a more potent inhibitor of serotonin uptake than the selective serotonin reuptake inhibitors (SSRIs) Citalopram, fluvoxamine and fluoxetine. Paroxetine was more potent than sertraline in one study that compared mean inhibition constants for serotonin uptake, but not in another study that compared the concentrations required to inhibit serotonin uptake by 50%. In contrast to the tricyclic antidepressants, paroxetine has little effect on the uptake of dopamine or noradrenaline (norepinephrine) in vitro. It has negligible affinity for αr(1-), αr(2-) and βr-adrenoceptors, dopamine D(1) and D(2) receptors, hi starnine H(1) receptors and serotonin 5-HT(1A), 5-HT(2A) and 5-HT(2C) receptors. However, paroxetine does have weak affinity for muscarinic cholinergic receptors. As shown in rats, paroxetine appears to indirectly activate somatodendritic 5-HT(1A) autoreceptors when initially administered, thereby inhibiting firing of 5-HT neurons and release of serotonin. This may explain why the onset of therapeutic effect of paroxetine is delayed. However, repeated administration of paroxetine causes adaptive changes in synaptic serotonergic receptors, including a decrease in the responsiveness of somatodendritic and terminal serotonin autoreceptors. Central βr-adrenoceptors are not down-regulated by administration of paroxetine to rats. Various studies in healthy volunteers without sleep disorders or volunteers reporting poor sleep have indicated that paroxetine disturbs normal sleep patterns by reducing rapid eye movement (REM) sleep time and lengthening REM latency. The effect of paroxetine on sleep in patients with panic disorder has not been determined, but in patients with depression the drug improves subjective quality of sleep. In electroencephalographic studies in healthy volunteers, administration of a single dose of paroxetine 30mg produced changes indicative of a sedative profile, whereas administration of 70mg produced changes indicative of activating properties. No significant impairment of psychomotor function was observed after administration of single or multiple doses of paroxetine 20 or 30mg to healthy volunteers or patients with depression. The sedation and impairment of psychomotor function caused by haloperidol, amobarbital, oxazepam or alcohol (ethanol) were not potentiated by the administration of paroxetine 30mg. In contrast to amitriptyline 150 mg/day or doxepin 150 mg/day, 2 to 6 weeks' treatment with paroxetine 20 or 30 mg/day did not produce clinically significant haemodynamic or electrophysiological effects on cardiac function in healthy volunteers or patients with depression. Fewer adverse cardiac effects were reported by paroxetine than nortriptyline recipients in a study in patients with depression and ischaemic heart disease. The anxiolytic activity of paroxetine has been demonstrated after 7 or 21 days' administration in several rodent models.

PHARMACOKINETIC PROPERTIES: Paroxetine is well absorbed after oral administration. It undergoes extensive first-pass metabolism and is rapidly distributed into tissue. Only about 1% of the paroxetine dose remains in the systemic circulation. Approximately 95% of paroxetine is protein bound in the plasma. Steady-state concentrations are reached after 7 to 14 days of oral administration and the terminal elimination half-life (t1/2βr) is approximately 24 hours. However, there is a great deal of interindividual variation in the pharmacokinetics of paroxetine. Paroxetine is metabolised by at least 2 enzymes of the cytochrome P450 (CYP) system, one of which is CYP2D6. This enzyme is subject to genetic polymorphism, and thus the pharmacokinetics of paroxetine differ between individuals who have the enzyme (extensive metabolisers) and those who do not (poor metabolisers). The metabolites of paroxetine are essentially inactive. Metabolism of paroxetine by CYP2D6 is saturable. Consequently, with repeated administration, bioavailability of paroxetine increases and pharmacokinetics may become nonlinear in some patients, especially when the dosage of paroxetine is increased. Approximately two-thirds of a paroxetine dose is eliminated in the urine and the remainder is excreted in faeces. Almost all of the dose is eliminated as metabolites; lt3% is excreted as unchanged drug. The plasma concentration and area under the plasma concentration-time curve of paroxetine are greater, and the t1/2βr prolonged, in elderly patients and those with hepatic or severe renal impairment compared with the general population. Paroxetine distributes into breast milk to produce concentrations similar to those in plasma.

THERAPEUTIC POTENTIAL: As shown in 3 short term placebo-controlled trials in patients with panic disorder with or without agoraphobia, oral paroxetine 10 to 60 mg/day is significantly more effective than placebo for most variables measuring reduction in panic attack frequency. The drug also produced significantly greater improvements in various anxiety and depression scales than placebo. An extension phase of one of the placebo-controlled studies showed that the efficacy of paroxetine in reducing panic attack frequency is maintained during up to 6 months' treatment and that the drug reduces the risk of relapse. Oral paroxetine 10 to 60 mg/day was at least as effective as clomipramine 10 to 150 mg/day in a comparative study. During weeks 7 to 9 of treatment, 51% of paroxetine recipients had no full panic attacks, compared with 37% of clomipramine recipients. The onset of action appeared to be more rapid for paroxetine than for clomipramine. The 2 drugs were equally effective in improving generalised anxiety, phobic avoidance and social, family and work interactions. In patients who elected to continue treatment for a further 36 weeks in an extension phase of the above study, response rates increased further in all groups, including the placebo group. During weeks 34 to 36 of extended treatment, 85% of paroxetine recipients, 72% of clomipramine recipients and 59% of placebo recipients had no panic attacks. The difference between paroxetine and placebo was statistically significant at this time point; however, there was no significant difference between groups at the primary efficacy endpoint (weeks 22 to 24).

TOLERABILITY: Paroxetine is generally well tolerated by both younger and older individuals and its adverse event profile is consistent with that expected for an SSRI. The tolerability profile of paroxetine in patients with panic disorder appears to resemble that in patients with depression. Headache, nausea, somnolence, dry mouth and insomnia were the most common adverse events among 469 patients with panic disorder who received paroxetine 10 to 60 mg/day in short term clinical trials. The individual incidences for these events ranged from 18 to 25%; however, the incidence of headache in paroxetine-treated patients was the same as that in placebo recipients. (ABSTRACT TRUNCATED)

References

  1. Psychopharmacology (Berl). 1989;97(1):96-8 - PubMed
  2. J Clin Psychiatry. 1996;57 Suppl 10:51-8; discussion 59-60 - PubMed
  3. J Clin Psychopharmacol. 1995 Apr;15(2):106-9 - PubMed
  4. Acta Psychiatr Scand Suppl. 1989;350:156-7 - PubMed
  5. Pharmacotherapy. 1995 Nov-Dec;15(6):778-80 - PubMed
  6. Acta Psychiatr Scand Suppl. 1989;350:41 - PubMed
  7. J Clin Psychiatry. 1990 Apr;51 Suppl:14-20; discussion 21 - PubMed
  8. Am J Psychiatry. 1994 Feb;151(2):289 - PubMed
  9. Int Clin Psychopharmacol. 1994 Jun;9 Suppl 3:13-9 - PubMed
  10. Acta Psychiatr Scand Suppl. 1989;350:93-4 - PubMed
  11. Acta Psychiatr Scand Suppl. 1989;350:89-90 - PubMed
  12. Acta Psychiatr Scand Suppl. 1989;350:53-5 - PubMed
  13. Int Clin Psychopharmacol. 1991 Dec;6 Suppl 3:49-55; discussion 55-6 - PubMed
  14. J Clin Psychopharmacol. 1994 Dec;14(6):392-5 - PubMed
  15. Eur J Clin Pharmacol. 1996;51(1):73-8 - PubMed
  16. Acta Psychiatr Scand Suppl. 1989;350:102-6 - PubMed
  17. J Clin Psychopharmacol. 1993 Oct;13(5):321-6 - PubMed
  18. Br J Clin Pharmacol. 1992 Sep;34(3):262-5 - PubMed
  19. Neuropharmacology. 1994 Dec;33(12):1581-8 - PubMed
  20. J Clin Psychiatry. 1996 Nov;57(11):519-22 - PubMed
  21. Am J Psychiatry. 1995 Apr;152(4):645-6 - PubMed
  22. Eur J Clin Pharmacol. 1993;44(4):349-55 - PubMed
  23. Psychopharmacology (Berl). 1984;83(4):327-9 - PubMed
  24. Gerontology. 1994;40 Suppl 1:21-7 - PubMed
  25. Pharmacotherapy. 1994 Mar-Apr;14(2):127-38 - PubMed
  26. Acta Psychiatr Scand Suppl. 1989;350:60-75 - PubMed
  27. Acta Psychiatr Scand Suppl. 1989;350:76-80 - PubMed
  28. Psychosomatics. 1995 Mar-Apr;36(2):159-60 - PubMed
  29. J Clin Psychiatry. 1996;57 Suppl 10:11-8; discussion 19-22 - PubMed
  30. Life Sci. 1990;47(18):1683-91 - PubMed
  31. Acta Psychiatr Scand Suppl. 1989;350:50-2 - PubMed
  32. J Psychopharmacol. 1993 Jan;7(4):325-30 - PubMed
  33. J Affect Disord. 1996 Sep 9;40(1-2):85-93 - PubMed
  34. J Clin Psychopharmacol. 1995 Oct;15(5):374-5 - PubMed
  35. Eur J Clin Pharmacol. 1991;41(4):351-4 - PubMed
  36. Br J Clin Pharmacol. 1986 Jul;22(1):97-9 - PubMed
  37. Int Clin Psychopharmacol. 1997 Jan;12(1):13-8 - PubMed
  38. J Clin Psychiatry. 1991 Feb;52 Suppl:18-23; discussion 24-5 - PubMed
  39. Acta Psychiatr Scand Suppl. 1989;350:31-3 - PubMed
  40. Br J Psychiatry. 1995 Sep;167(3):374-9 - PubMed
  41. Sleep. 1991 Oct;14(5):439-47 - PubMed
  42. Psychopharmacology (Berl). 1996 Jul;126(1):50-4 - PubMed
  43. Clin Pharmacol Ther. 1992 Mar;51(3):278-87 - PubMed
  44. Arch Gen Psychiatry. 1993 Jan;50(1):44-50 - PubMed
  45. J Clin Psychopharmacol. 1996 Aug;16(4):299-306 - PubMed
  46. J Clin Psychiatry. 1990 Dec;51 Suppl A:24-30 - PubMed
  47. Am J Psychiatry. 1995 May;152(5):810 - PubMed
  48. Psychopharmacology (Berl). 1987;93(2):193-200 - PubMed
  49. Acta Psychiatr Scand Suppl. 1989;350:99-101 - PubMed
  50. Br J Psychiatry. 1991 Sep;159:394-8 - PubMed
  51. CMAJ. 1996 Sep 1;155(5):519-27 - PubMed
  52. Ann Pharmacother. 1993 Oct;27(10):1212-22 - PubMed
  53. Int Clin Psychopharmacol. 1992 Jun;6 Suppl 4:69-80 - PubMed
  54. Acta Psychiatr Scand Suppl. 1989;350:95-8 - PubMed
  55. Eur J Pharmacol. 1994 Aug 1;260(2-3):251-5 - PubMed
  56. Psychiatry Res. 1996 Jan 31;59(3):189-96 - PubMed
  57. Epilepsy Res. 1991 Nov-Dec;10(2-3):201-4 - PubMed
  58. Pharmacol Biochem Behav. 1994 Oct;49(2):281-5 - PubMed
  59. Int Clin Psychopharmacol. 1994 Mar;9 Suppl 1:19-26 - PubMed
  60. Int Clin Psychopharmacol. 1995 Jun;10(2):83-93 - PubMed
  61. J Clin Psychopharmacol. 1992 Aug;12(4):251-61 - PubMed
  62. Am J Psychiatry. 1995 Aug;152(8):1235-4 - PubMed
  63. Vet Hum Toxicol. 1997 Apr;39(2):86-8 - PubMed
  64. Pharmacol Toxicol. 1996 Apr;78(4):203-8 - PubMed
  65. J Clin Psychopharmacol. 1996 Jun;16(3):218-22 - PubMed
  66. Acta Psychiatr Scand Suppl. 1989;350:42-4 - PubMed
  67. Lancet. 1995 Jul 1;346(8966):57 - PubMed
  68. Drugs. 1991 Feb;41(2):225-53 - PubMed
  69. Eur Neuropsychopharmacol. 1995 Mar;5(1):5-13 - PubMed
  70. Psychopharmacology (Berl). 1990;102(3):379-82 - PubMed
  71. Int Clin Psychopharmacol. 1996 Sep;11(3):187-91 - PubMed
  72. J Clin Psychopharmacol. 1990 Apr;10(2):119-21 - PubMed
  73. J Am Acad Child Adolesc Psychiatry. 1994 Sep;33(7):1060-1 - PubMed
  74. J Clin Psychiatry. 1992 Feb;53 Suppl:7-12 - PubMed
  75. Acta Psychiatr Scand. 1997 Feb;95(2):145-52 - PubMed
  76. J Clin Psychiatry. 1996;57 Suppl 10:23-31; discussion 32-3 - PubMed
  77. Br J Psychiatry. 1997 Jun;170:549-53 - PubMed
  78. J Clin Psychopharmacol. 1987 Oct;7(5):329-32 - PubMed
  79. Acta Psychiatr Scand Suppl. 1989;350:45 - PubMed
  80. Psychopharmacology (Berl). 1997 Feb;129(3):197-205 - PubMed
  81. Pharmacotherapy. 1995 Nov-Dec;15(6 Pt 2):84S-99S - PubMed
  82. Acta Psychiatr Scand Suppl. 1989;350:85-6 - PubMed
  83. Psychopharmacology (Berl). 1981;75(3):236-9 - PubMed
  84. Neuropsychopharmacology. 1991 Dec;5(4):219-29 - PubMed
  85. Int Clin Psychopharmacol. 1992 Jun;6 Suppl 5:21-39 - PubMed
  86. Int Clin Psychopharmacol. 1992 Jun;6 Suppl 4:53-8 - PubMed
  87. J Clin Psychiatry. 1995 Feb;56(2):82-3 - PubMed
  88. Pharmacoeconomics. 1995 Jul;8(1):62-81 - PubMed
  89. Int Clin Psychopharmacol. 1992 Nov;7(2):101-8 - PubMed
  90. J Clin Psychopharmacol. 1994 Jun;14(3):206-7 - PubMed
  91. Acta Psychiatr Scand Suppl. 1989;350:21-3 - PubMed
  92. J Clin Psychiatry. 1996;57 Suppl 10:44-8; discussion 49-50 - PubMed
  93. Am J Psychiatry. 1995 Jan;152(1):149-50 - PubMed
  94. Drugs. 1992;43 Suppl 2:40-6; discussion 46-7 - PubMed
  95. Clin Pharmacol Ther. 1992 Mar;51(3):288-95 - PubMed
  96. J Psychopharmacol. 1993 Jan;7(4):316-24 - PubMed
  97. Acta Psychiatr Scand Suppl. 1989;350:24-6 - PubMed
  98. Int Clin Psychopharmacol. 1995 Mar;10(1):45-9 - PubMed
  99. Headache. 1995 Sep;35(8):488-9 - PubMed
  100. Eur Neuropsychopharmacol. 1995 Mar;5(1):35-42 - PubMed
  101. J Clin Psychiatry. 1996;57 Suppl 10:3-8; discussion 9-10 - PubMed
  102. Br J Clin Pharmacol. 1992 May;33(5):521-3 - PubMed
  103. Drugs. 1995 Mar;49(3):328-44 - PubMed
  104. Am J Psychiatry. 1995 Nov;152(11):1689 - PubMed
  105. J Clin Psychiatry. 1996;57 Suppl 2:46-52 - PubMed
  106. Ann Pharmacother. 1994 Dec;28(12):1359-69 - PubMed
  107. Int Clin Psychopharmacol. 1992 Jun;6 Suppl 4:15-24 - PubMed
  108. J Clin Psychiatry. 1992 Feb;53 Suppl:61-6 - PubMed
  109. Int Clin Psychopharmacol. 1992 Jun;6 Suppl 4:65-7 - PubMed
  110. Behav Brain Res. 1996;73(1-2):281-3 - PubMed
  111. Acta Psychiatr Scand. 1993 May;87(5):302-5 - PubMed
  112. Acta Psychiatr Scand. 1997 Feb;95(2):153-60 - PubMed
  113. J Am Acad Child Adolesc Psychiatry. 1995 Mar;34(3):263-4 - PubMed

Publication Types